The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...
After adjustment for density, the hazard ratios were 2.04 and 4.47 for intermediate-and high-risk AI categories.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback